Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2016 | 1 |
2019 | 4 |
2020 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy.
Cancer Biother Radiopharm. 2020 Sep;35(7):497-510. doi: 10.1089/cbr.2020.3568. Epub 2020 Apr 7.
Cancer Biother Radiopharm. 2020.
PMID: 32255671
Free PMC article.
Review.
Tumor growth inhibition and immune system activation following treatment with thorium-227 conjugates and PD-1 check-point inhibition in the MC-38 murine model.
Berg-Larsen A, Mobergslien A, Moen I, Petros G, Kristian A, Gunvaldsen KS, Cruciani V, Wickstroem K, Bjerke RM, Karlsson J, Cuthbertson A.
Berg-Larsen A, et al. Among authors: wickstroem k.
Front Med (Lausanne). 2022 Nov 15;9:1033303. doi: 10.3389/fmed.2022.1033303. eCollection 2022.
Front Med (Lausanne). 2022.
PMID: 36457578
Free PMC article.
Item in Clipboard
Preclinical Combination Studies of an FGFR2 Targeted Thorium-227 Conjugate and the ATR Inhibitor BAY 1895344.
Wickstroem K, Hagemann UB, Kristian A, Ellingsen C, Sommer A, Ellinger-Ziegelbauer H, Wirnitzer U, Hagelin EM, Larsen A, Smeets R, Bjerke RM, Karlsson J, Ryan OB, Wengner AM, Linden L, Mumberg D, Cuthbertson AS.
Wickstroem K, et al.
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):410-422. doi: 10.1016/j.ijrobp.2019.06.2508. Epub 2019 Jun 27.
Int J Radiat Oncol Biol Phys. 2019.
PMID: 31255687
Item in Clipboard
Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB, Ellingsen C, Schuhmacher J, Kristian A, Mobergslien A, Cruciani V, Wickstroem K, Schatz CA, Kneip C, Golfier S, Smeets R, Uran S, Hennekes H, Karlsson J, Bjerke RM, Ryan OB, Mumberg D, Ziegelbauer K, Cuthbertson AS.
Hagemann UB, et al. Among authors: wickstroem k.
Clin Cancer Res. 2019 Aug 1;25(15):4723-4734. doi: 10.1158/1078-0432.CCR-18-3476. Epub 2019 May 7.
Clin Cancer Res. 2019.
PMID: 31064781
Item in Clipboard
Synergistic Effect of a Mesothelin-Targeted 227Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models.
Wickstroem K, Hagemann UB, Cruciani V, Wengner AM, Kristian A, Ellingsen C, Siemeister G, Bjerke RM, Karlsson J, Ryan OB, Linden L, Mumberg D, Ziegelbauer K, Cuthbertson AS.
Wickstroem K, et al.
J Nucl Med. 2019 Sep;60(9):1293-1300. doi: 10.2967/jnumed.118.223701. Epub 2019 Mar 8.
J Nucl Med. 2019.
PMID: 30850485
Free PMC article.
Item in Clipboard
Synergistic Effect of a HER2 Targeted Thorium-227 Conjugate in Combination with Olaparib in a BRCA2 Deficient Xenograft Model.
Wickstroem K, Karlsson J, Ellingsen C, Cruciani V, Kristian A, Hagemann UB, Bjerke RM, Ryan OB, Linden L, Mumberg D, Brands M, Cuthbertson A.
Wickstroem K, et al.
Pharmaceuticals (Basel). 2019 Oct 15;12(4):155. doi: 10.3390/ph12040155.
Pharmaceuticals (Basel). 2019.
PMID: 31618864
Free PMC article.
Item in Clipboard
In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia.
Hagemann UB, Wickstroem K, Wang E, Shea AO, Sponheim K, Karlsson J, Bjerke RM, Ryan OB, Cuthbertson AS.
Hagemann UB, et al. Among authors: wickstroem k.
Mol Cancer Ther. 2016 Oct;15(10):2422-2431. doi: 10.1158/1535-7163.MCT-16-0251. Epub 2016 Aug 17.
Mol Cancer Ther. 2016.
PMID: 27535972
Item in Clipboard
Cite
Cite